About CannEpil®<\/b> <\/div>\n
CannEpil® is a phytocannabinoid derived Investigational Medicinal Product designed to treat Drug Resistant Epilepsy with a high CBD, low THC formula, and was made available for distribution and prescription in Ireland<\/span> in 2019 as part of the Ireland’s<\/span> Medical Cannabis Access Programme. A research report prepared by Alacrita, a life sciences consulting company, suggested potential market in the agreement territories of 150,000 adults and children suffering from refractory epilepsy^{1<\/sup>. <\/p>\n}
About CogniCann®<\/b> <\/div>\n
CogniCann® is a phytocannabinoid derived Investigational Medicinal Product designed to treat patients with Dementia and Alzheimer’s disease, and is undergoing a Phase II clinical trial at the University of Notre Dame<\/span> in Perth<\/span>, Western Australia<\/span>, which has been designed to evaluate the potential behavioural benefits of CogniCann® on patients suffering from these ailments.<\/p>\n
About MGC Pharma<\/b> <\/div>\n
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC, OTC: MGCLF) is a European based bio-pharma company developing and supplying affordable standardized phytomedicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe<\/span>, North America<\/span> and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions \u2013 Epilepsy and Dementia \u2013 and has further products in the development pipeline. <\/p>\n
Employing its ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimize cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company’s EU-GMP Certified manufacturing facility. <\/p>\n
Recent research highlights the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.<\/p>\n
MGC Pharma has a growing patient base in Australia<\/span>, the UK, Brazil<\/span> and Ireland<\/span> and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. <\/p>\n
Follow us through our social media channels:<\/i><\/p>\n
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
https:\/\/mgcpharma.com.au<\/a> <\/p>\n
About Sciensus Rare<\/b> <\/div>\n
Science International B.V. trading as Sciensus Rare, is the dedicated and enhanced rare disease medicines service business within the Sciensus group of companies, the largest speciality pharmacy provider in Europe<\/span>, of complex medication management in a home environment.<\/p>\n
Sciensus Rare is a speciality pharmacy focused on rare diseases, providing turnkey services for emerging and medium-sized biotech organizations, achieving market access for their products in Europe<\/span> and beyond. Sciensus Rare offers five main services; decentralized clinical trials, medicines access, tailored supply chain management, patient and family support and outcome monitoring.<\/p>\n
www.sciensusrare.com<\/a><\/p>\n
For further information please contact:<\/b><\/p>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
MGC Pharmaceuticals Ltd<\/b><\/span><\/p>\n<\/td>\n
\n
MGC Pharmaceuticals Ltd<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n
\n
Roby Zomer<\/span><\/p>\n<\/td>\n
\n
David Lim<\/span><\/p>\n<\/td>\n<\/tr>\n
\n
CEO & Managing Director<\/span><\/p>\n<\/td>\n
\n
Company Secretary<\/span><\/p>\n<\/td>\n<\/tr>\n
\n
+61 8 6382 3390<\/span><\/p>\n<\/td>\n
\n
+61 8 6382 3390<\/span><\/p>\n<\/td>\n<\/tr>\n
\n
info@mgcpharma.com.au<\/a> <\/span><\/p>\n<\/td>\n
\n
info@mgcpharma.com.au<\/a><\/span><\/p>\n<\/td>\n<\/tr>\n
<\/td>\n <\/td>\n<\/tr>\n
\n
UK Broker \u2013 Turner Pope<\/b><\/span><\/p>\n<\/td>\n
\n
UK PR Advisors \u2013 Tavistock<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n
\n
Andy Thacker \/ James Pope<\/span><\/p>\n<\/td>\n
\n
Charles Vivian \/ Tim Pearson<\/span><\/p>\n<\/td>\n<\/tr>\n
\n
+44 203 657 0050<\/span><\/p>\n<\/td>\n
\n
+44 207 920 3150<\/span><\/p>\n<\/td>\n<\/tr>\n
\n
info@turnerpope.com<\/a><\/span><\/p>\n<\/td>\n
\n
mgcpharma@tavistock.co.uk<\/a><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n
^1<\/sup>https:\/\/mgcpharma.com.au\/wp-content\/uploads\/sites\/11\/2021\/11\/Alacrita-Research-Report-MXC-1.pdf<\/a> <\/p>\n
Logo - https:\/\/mma.prnasia.com\/media2\/1780050\/mgcpharma_logo.jpg?p=medium600<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
LONDON, April 5, 2022 \/PRNewswire\/ – MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[105],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/100731"}],"collection":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/comments?post=100731"}],"version-history":[{"count":0,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/100731\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/media?parent=100731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/categories?post=100731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/tags?post=100731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}